ZA200608412B - Novel 2-[1-aza-bicyclo (2.2.2)oct-3-yl)-2,3-dihydroisoindol-1-one/5/6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor - Google Patents

Novel 2-[1-aza-bicyclo (2.2.2)oct-3-yl)-2,3-dihydroisoindol-1-one/5/6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor

Info

Publication number
ZA200608412B
ZA200608412B ZA200608412A ZA200608412A ZA200608412B ZA 200608412 B ZA200608412 B ZA 200608412B ZA 200608412 A ZA200608412 A ZA 200608412A ZA 200608412 A ZA200608412 A ZA 200608412A ZA 200608412 B ZA200608412 B ZA 200608412B
Authority
ZA
South Africa
Prior art keywords
dihydroisoindol
furo
pyrrol
aza
bicyclo
Prior art date
Application number
ZA200608412A
Other languages
English (en)
Inventor
Chapdelaine Marc
Keith J Herzog
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200608412B publication Critical patent/ZA200608412B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA200608412A 2004-04-14 2006-10-09 Novel 2-[1-aza-bicyclo (2.2.2)oct-3-yl)-2,3-dihydroisoindol-1-one/5/6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor ZA200608412B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0400970A SE0400970D0 (sv) 2004-04-14 2004-04-14 Nicotinic acetylcholine receptor ligands

Publications (1)

Publication Number Publication Date
ZA200608412B true ZA200608412B (en) 2008-09-25

Family

ID=32294312

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200608412A ZA200608412B (en) 2004-04-14 2006-10-09 Novel 2-[1-aza-bicyclo (2.2.2)oct-3-yl)-2,3-dihydroisoindol-1-one/5/6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor

Country Status (14)

Country Link
US (1) US7566727B2 (fr)
EP (1) EP1737854A1 (fr)
JP (1) JP2007532637A (fr)
CN (1) CN1968951A (fr)
AU (1) AU2005233492B2 (fr)
BR (1) BRPI0509777A (fr)
CA (1) CA2563010A1 (fr)
IL (1) IL178241A0 (fr)
NO (1) NO20065199L (fr)
RU (2) RU2372350C2 (fr)
SE (1) SE0400970D0 (fr)
UA (1) UA86617C2 (fr)
WO (1) WO2005100351A1 (fr)
ZA (1) ZA200608412B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
TW200804281A (en) * 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
EP2215074B1 (fr) * 2007-09-27 2014-02-19 The United States of America, as Represented by the Secretary, Department of Health and Human Services Composés d'isoindoline pour le traitement d'une amyotrophie spinale et autres utilisations
US7790760B2 (en) 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
US8669259B2 (en) 2009-08-26 2014-03-11 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
KR101758046B1 (ko) * 2009-12-22 2017-07-14 버텍스 파마슈티칼스 인코포레이티드 포스파티딜이노시톨 3-키나제의 이소인돌리논 억제제
NZ601526A (en) 2009-12-31 2014-07-25 Piramal Entpr Ltd Inhibitors of diacylglycerol acyl transferase
JO3383B1 (ar) * 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
TW201726675A (zh) 2015-12-23 2017-08-01 默沙東藥廠 M4毒蕈鹼乙醯膽鹼受體之異位調節劑6,7-二氫-5h-吡咯并[3,4-b]吡啶-5-酮
WO2017107089A1 (fr) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. Modulateurs allostériques 3-(1h-pyrazol-4-yl)pyridine du récepteur muscarinique m4 de l'acétylcholine
US10040804B2 (en) 2016-12-21 2018-08-07 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
WO2018112843A1 (fr) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Modulateurs allostériques d'éther hétéroarylpipéridine du récepteur muscarinique de l'acétylcholine m4
WO2018112842A1 (fr) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Modulateurs allostériques d'éther hétéroarylpipéridine 6,6-fusionné du récepteur muscarinique de l'acétylcholine m4
WO2018210229A1 (fr) * 2017-05-18 2018-11-22 南京明德新药研发股份有限公司 Agoniste du récepteur nicotinique de l'acétylcholine alpha-7 et application de celui-ci
CN107188900B (zh) * 2017-05-27 2019-09-06 北京师范大学 α7烟碱型乙酰胆碱受体的配体化合物及其应用
WO2018226545A1 (fr) * 2017-06-09 2018-12-13 Merck Sharp & Dohme Corp. Azabicyclo[4.1.0]heptanes modulateurs allostériques du récepteur muscarinique m4 de l'acétylcholine
WO2019000238A1 (fr) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. Modulateurs allostériques de 5-(pyridin-3-yl)oxazole du récepteur muscarinique m4 de l'acétylcholine
WO2019000237A1 (fr) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. Modulateurs allostériques de 3-(1h-pyrazol-4-yl)pyridine du récepteur muscarinique m4 de l'acétylcholine
WO2019000236A1 (fr) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. Modulateurs allostériques de 3-(1h-pyrazol-4-yl)pyridine du récepteur muscarinique m4 de l'acétylcholine
NL2021185B1 (en) 2018-06-26 2020-01-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combination Therapy and Use Thereof for Treating Cancer
WO2022115301A1 (fr) * 2020-11-24 2022-06-02 Merck Sharp & Dohme Corp. Isoindolinones modifiées en tant qu'inhibiteurs de glucosylcéramide synthase

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
SE9201478D0 (sv) 1992-05-11 1992-05-11 Kabi Pharmacia Ab Heteroaromatic quinuclidinenes, their use and preparation
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
IT1303123B1 (it) 1998-10-13 2000-10-30 Rotta Research Lab Derivati basici di benz(e)isoindol-1-oni e pirrolo(3,4-c)chinolin-1-oni ad attivita' 5ht3 antagonista, loro preparazione ed
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
ATE385497T1 (de) * 2000-12-01 2008-02-15 Neurosearch As 3-substituierte quinuclidin-derivate und deren verwendung als nikotinischen agonisten
DE10118551A1 (de) 2001-04-14 2002-10-17 Merck Patent Gmbh Nikotinische Acetylcholinrezeptor Liganden
AU2002320958B2 (en) 2001-07-06 2008-02-28 Neurosearch A/S Novel compounds, their preparation and use
WO2004016608A1 (fr) 2002-08-14 2004-02-26 Neurosearch A/S Nouveaux derives quinuclidiniques et leur utilisation

Also Published As

Publication number Publication date
NO20065199L (no) 2006-11-13
IL178241A0 (en) 2006-12-31
RU2372350C2 (ru) 2009-11-10
CN1968951A (zh) 2007-05-23
WO2005100351A1 (fr) 2005-10-27
SE0400970D0 (sv) 2004-04-14
RU2009126341A (ru) 2011-01-20
US7566727B2 (en) 2009-07-28
BRPI0509777A (pt) 2007-10-23
EP1737854A1 (fr) 2007-01-03
CA2563010A1 (fr) 2005-10-27
RU2006135481A (ru) 2008-05-20
JP2007532637A (ja) 2007-11-15
AU2005233492A1 (en) 2005-10-27
AU2005233492B2 (en) 2009-06-11
UA86617C2 (en) 2009-05-12
US20070213342A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
ZA200608412B (en) Novel 2-[1-aza-bicyclo (2.2.2)oct-3-yl)-2,3-dihydroisoindol-1-one/5/6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor
HUP0401849A3 (en) Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
DE60038823D1 (de) Diazabicycloderivate als Nikotin-Acetylcholin-Rezeptorliganden
AU2003214936A1 (en) Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
IL183568A (en) Process for making 7,8-dihydro-5 h-patridine-6-onh
IL225968A0 (en) 1- Aza-bicyclo [3.3.1] nonanes
IL172762A0 (en) Spiro [1-azabicyclo [2.2.2]octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
ZA200200232B (en) Quinuclidine derivatives and their use as muscarinic M3 receptor ligands.
ZA200402472B (en) Method for preparing benzenesulfonyl compounds.
IL161120A0 (en) Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1
AU2001259051A1 (en) Piperidyindoles as serotonin receptor ligands
ZA200609639B (en) Method for preparing N-piperidino-1,5-diphenylpyrazole-3-carboxamide derivatives
EP1545508A4 (fr) Derives d'azabicyclo ¬3.1.0 hexane 3,6-disubstitues, utiles en tant qu'agonistes de recepteurs muscariniques
ATE295835T1 (de) (2-azabicyclo (2.2.1)hept-7-yl)methanol-derivate als nikotinische acetylcholinrezeptor agonisten
HK1101636A (en) Novel 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-l-one/5,6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor
ZA200702070B (en) Process for preparing substituted 8-azablcyclo[3.2.1] octan-3-ols
ZA200705106B (en) Nicotinic acetycholine receptor ligands
ZA200701015B (en) Antagonizing interleukin-21 receptor activity
IL176073A0 (en) Nicotinic acetylcholine receptor ligands
MXPA03004679A (es) Procedimiento para preparar derivados de distamicina.
ZA200502316B (en) 4-Oxo-4,6,7,8-tetrahydrop-pyrrolofÄ1,2-aÜpyrazine-6-carbox-amide compounds, a process for their preparation and pharmaceutical compositions containingthem.
WO2006055245A3 (fr) Methode de preparation de composes de pyrazolopyridine
HK1098752A (en) Process for preparing substituted 8-azabicyclo[3.2.1] octan-3-ols
AU2531101A (en) 9-azabicyclo(4.2.1)non-2-ene derivatives as ligands for nicotinic acetylcholine receptors
HK1089162A (en) Spiro [1-azabicyclo [2.2.2]octan-3,5'-oxazolidin-2'-one] derivatives with affinity to the alpha7 nicotinic acetylcholine receptor